Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGEN
CUSIPN/A
Phone972-3765-8585
Debt
Debt-to-Equity RatioN/A
Current Ratio5.81
Quick Ratio5.81
Price-To-Earnings
Trailing P/E Ratio-5.07
Forward P/E Ratio-8.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$710,000.00
Price / Sales263.67
Cash FlowN/A
Price / CashN/A
Book Value$0.57 per share
Price / Book6.40
Profitability
EPS (Most Recent Fiscal Year)($0.72)
Net Income$-37,060,000.00
Net MarginsN/A
Return on Equity-78.00%
Return on Assets-62.61%
Miscellaneous
Employees101
Outstanding Shares51,290,000
Compugen (NASDAQ:CGEN) Frequently Asked Questions
What is Compugen's stock symbol?
Compugen trades on the NASDAQ under the ticker symbol "CGEN."
How were Compugen's earnings last quarter?
Compugen Ltd. (NASDAQ:CGEN) posted its quarterly earnings results on Tuesday, August, 2nd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.04. The biotechnology company earned $0.50 million during the quarter, compared to analyst estimates of $0.11 million. View Compugen's Earnings History.
When is Compugen's next earnings date?
What price target have analysts set for CGEN?
2 analysts have issued 12-month price targets for Compugen's shares. Their forecasts range from $9.00 to $9.00. On average, they expect Compugen's stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Compugen.
Who are some of Compugen's key competitors?
Some companies that are related to Compugen include Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Mesoblast (MESO), CASI Pharmaceuticals (CASI), Scholar Rock (SRRK), Surface Oncology (SURF), Nightstar Therapeutics (NITE), Vericel (VCEL), Adverum Biotechnologies (ADVM), NanoString Technologies (NSTG), PDL BioPharma (PDLI), Cellular Biomedicine Group (CBMG) and Osiris Therapeutics (OSIR).
Who are Compugen's key executives?
Compugen's management team includes the folowing people:
- Dr. Anat Cohen-Dayag, Chief Exec. Officer, Pres and Director (Age 51)
- Mr. Ari Krashin, Chief Financial and Operating Officer (Age 45)
- Mr. Kirk A. Christoffersen MBA, Sr. VP of Corp. and Bus. Devel. (Age 49)
- Dr. Zurit Levine Ph.D., VP of Research & Discovery (Age 50)
- Dr. John J. Hunter, VP of Antibody R&D (Age 55)
Has Compugen been receiving favorable news coverage?
News stories about CGEN stock have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Compugen earned a news impact score of 0.13 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 44.39 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Compugen's major shareholders?
Compugen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include UBS Group AG (0.62%), Jane Street Group LLC (0.20%) and A.R.T. Advisors LLC (0.12%). View Institutional Ownership Trends for Compugen.
Which institutional investors are buying Compugen stock?
How do I buy shares of Compugen?
Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Compugen's stock price today?
One share of CGEN stock can currently be purchased for approximately $3.65.
How big of a company is Compugen?
Compugen has a market capitalization of $187.22 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-37,060,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Compugen employs 101 workers across the globe.
How can I contact Compugen?
Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]
MarketBeat Community Rating for Compugen (CGEN)
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
